{"id":2349,"date":"2017-09-28T17:47:40","date_gmt":"2017-09-28T12:17:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2349"},"modified":"2021-07-24T12:56:51","modified_gmt":"2021-07-24T07:26:51","slug":"notizia-52","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-52","title":{"rendered":"Alzeimer\u2019s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f7516b51135\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f7516b51135\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\/#Another_flop_for_Alzeimers_as_Late_Stage_drug_of_AxovantSciences_fails_in_trial\" >Another flop for Alzeimer\u2019s as Late Stage drug of AxovantSciences fails in trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\/#Guardant_Health_receives_IDE_approval_to_conduct_clinical_trial_for_Mercks_drug\" >Guardant Health receives IDE approval to conduct clinical trial for Merck\u2019s drug<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\/#First_Patient_Dosed_in_Phase_1_Clinical_Trial_of_Personalized_Immunotherapy_pLADD_according_to_Aduro_Biotech\" >First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD according to Aduro Biotech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\/#Sunny_Pharmtech_and_Vitruvias_Therapeutics_Receive_First_FDA_Generic_Drug_Approval\" >Sunny Pharmtech and Vitruvias Therapeutics Receive First FDA Generic Drug Approval<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Another_flop_for_Alzeimers_as_Late_Stage_drug_of_AxovantSciences_fails_in_trial\"><\/span>Another flop for Alzeimer\u2019s as Late Stage drug of AxovantSciences fails in trial<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer&#8217;s symptoms in participants of the trail. The news had plunged the Wall Street into another wave of disappointment for this therapy area, as it has been for decades for Alzheimer\u2019s. The company had not promised it to cure the disease but had hoped that it would delay the worst symptoms of Alzheimer\u2019s. However, the trial results clearly showed that no remarkable difference was observed between placebo and Interpirdine results in a 1,150 patient\u2019s trial.Axovant, a well-funded and hotly debated company, lost about 70 percent of its value in early-morning trading Tuesday. The New York firm was worth more than $2.6 billion before the news of intepirdine\u2019s failure. The drug\u2019s negative results did not surprise many in the industry, given that it had failed four previous clinical trials. Other drugs that work the same way have also fallen short.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Guardant_Health_receives_IDE_approval_to_conduct_clinical_trial_for_Mercks_drug\"><\/span>Guardant Health receives IDE approval to conduct clinical trial for Merck\u2019s drug<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The US Food and Drug Administration has approved the application for conducting a clinical trial to Guardant Health and has given them the go-ahead to use an investigational device to provide genomic testing for cancer patients, under the investigational device exemption approval. This will help Guardant provide testing for a clinical trial that assesses Merck\u2019s c-Met Kinase Inhibitor, a small molecule known as tepotinib. As for the device, Merck is set to use the Guardant&#8217;s liquid biopsy test Guardant360 CDx to identify patients with Met exon 14 skipping alterations who may qualify for the ongoing Phase II tepotinib trial. This screening process will help Merck target population for better and efficacious results of tepotinib.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"First_Patient_Dosed_in_Phase_1_Clinical_Trial_of_Personalized_Immunotherapy_pLADD_according_to_Aduro_Biotech\"><\/span>First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD according to Aduro Biotech<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Aduro Biotech, Inc has announced that first patient has been dosed in the Phase 1 clinical trial designed to evaluate the safety and tolerability of a personalized live, attenuated double-deleted Listeria monocytogenes (pLADD) immunotherapy for adults with metastatic colorectal cancer that is microsatellite stable (MSS).\u00a0The personalized immunotherapy has been engineered with patient-specific neoantigens that were identified and selected using state-of-the-art neoantigen identification technology developed by HanleeJi, M.D., associate professor of medicine at the Stanford University School of Medicine.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Sunny_Pharmtech_and_Vitruvias_Therapeutics_Receive_First_FDA_Generic_Drug_Approval\"><\/span>Sunny Pharmtech and Vitruvias Therapeutics Receive First FDA Generic Drug Approval<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Sunny PharmtechInc and Vitruvias Therapeutics LLC are collectively working on a generic product. Currently, they have received approval for their abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Lidocaine Ointment USP 5%.The generic is the first drug approved under the two companies\u2019 joint development agreement that includes eight products.The joint application was filed in November of 2016 and received first-cycle approval after a 10 month review.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Another flop for Alzeimer\u2019s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer&#8217;s symptoms in participants of the trail. The news had plunged the Wall Street into another wave of disappointment for this therapy area, as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1066,1407,1058,980,169,204,704,1060,1064,1061,1059,1055,395,1062,420,730,712,639,1057,1065,5789,1067,1063,1068],"industry":[17225],"therapeutic_areas":[17227,17245,17228],"class_list":["post-2349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aduro-biotech","tag-alzheimer","tag-axovantsciences","tag-biotech-news","tag-clinical-trials","tag-delveinsight","tag-fda","tag-guardant-health","tag-guardant360","tag-ide","tag-intepirdines","tag-latest-pharma","tag-merck","tag-mercks","tag-news","tag-notizia","tag-pharma-industry","tag-pharma-news","tag-phase","tag-pladd","tag-recent-pharma-news","tag-sunny-pharmtech","tag-tepotinib","tag-vitruvias-therapeutics","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alzeimer\u2019s drug; Guardant Health receives approval<\/title>\n<meta name=\"description\" content=\"Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdine could not suppress Alzheimer&#039;s symptoms...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzeimer\u2019s drug; Guardant Health receives approval\" \/>\n<meta property=\"og:description\" content=\"Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdine could not suppress Alzheimer&#039;s symptoms...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-52\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-28T12:17:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzeimer\u2019s drug; Guardant Health receives approval","description":"Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdine could not suppress Alzheimer's symptoms...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-52","og_locale":"en_US","og_type":"article","og_title":"Alzeimer\u2019s drug; Guardant Health receives approval","og_description":"Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdine could not suppress Alzheimer's symptoms...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-52","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-28T12:17:40+00:00","article_modified_time":"2021-07-24T07:26:51+00:00","og_image":[{"width":750,"height":315,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-52","url":"https:\/\/www.delveinsight.com\/blog\/notizia-52","name":"Alzeimer\u2019s drug; Guardant Health receives approval","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-52#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-52#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","datePublished":"2017-09-28T12:17:40+00:00","dateModified":"2021-07-24T07:26:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Axovant Sciences\u00a0has reported the failure of their late-stage trial involving the testing of its pill Intepirdine could not suppress Alzheimer's symptoms...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-52"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-52#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","width":750,"height":315,"caption":"Notizia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315-300x126.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aduro Biotech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AxovantSciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biotech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Guardant Health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Guardant360<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IDE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">intepirdine\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">latest pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">phase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pLADD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sunny Pharmtech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tepotinib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vitruvias Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aduro Biotech<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer<\/span>","<span class=\"advgb-post-tax-term\">AxovantSciences<\/span>","<span class=\"advgb-post-tax-term\">Biotech News<\/span>","<span class=\"advgb-post-tax-term\">Clinical trials<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Guardant Health<\/span>","<span class=\"advgb-post-tax-term\">Guardant360<\/span>","<span class=\"advgb-post-tax-term\">IDE<\/span>","<span class=\"advgb-post-tax-term\">intepirdine\u2019s<\/span>","<span class=\"advgb-post-tax-term\">latest pharma<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Merck\u2019s<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">phase<\/span>","<span class=\"advgb-post-tax-term\">pLADD<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sunny Pharmtech<\/span>","<span class=\"advgb-post-tax-term\">tepotinib<\/span>","<span class=\"advgb-post-tax-term\">Vitruvias Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 28, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 28, 2017 5:47 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2349"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2349\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2303"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2349"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2349"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}